Navigation Links
AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health

BETHESDA, Md., May 27 /PRNewswire/ -- A new public-private partnership between AstraZeneca and NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on supporting the work of the Drug-Induced Liver Injury Network (DILIN).  DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induce liver injury as well as effective screening, diagnostic and treatment options.  

Drug-induced liver injury, whether caused by prescription or non-prescription medication, is the most common cause of acute liver failure in the United States. It is the major reason for non-approval, withdrawal and limiting the prescribing of medications by the Food and Drug Administration.

Under the terms of the partnership, AstraZeneca will join other companies to provide funding for the project.  AstraZeneca will also have a seat on a DILIN scientific board, a group convened by FNIH that includes representatives of all the partners in this endeavor, to provide expertise and input on scientific and technical matters.  No details of the financial support were disclosed.  

"AstraZeneca is keen to support this important project to help the industry and the medical community better understand and mitigate the risks of liver damage associated with the use of some medicines," said Joachim Forsgren, VP and Global Head of Patient Safety at AstraZeneca.  "The safety of patients who need drugs to treat many different kinds of conditions and illnesses is paramount in both developing new medicines and safely and effectively using products currently on the market. We want to play our part in furthering this critical work, which will provide valuable insight to all those engaged in the research and development of drugs."

"We welcome the support of AstraZeneca's underlying commitment to work with the Foundation for NIH, and NIH, as we pursue advances in research and potential treatment options for drug-induced liver injury. Bringing together a team of experts in a collaborative environment is essential to this project's overall success," said Foundation for NIH Chairman, Charles A. Sanders, M.D.  

NIDDK launched the Drug-Induced Liver Injury Network in 2004 to address this increasingly frequent health problem, The network gathers clinical information and biological specimens in cases of suspected liver injury due to drug and/or herbal remedy use and promotes research on the underlying causes, means of prevention, and approaches to management and therapy.


Foundation for NIH.   For additional information about the Foundation for NIH, please visit

Established by the United States Congress to support the mission of the NIH—improving health through scientific discovery in the search for cures—the Foundation for NIH is a leader in identifying and addressing complex scientific and health issues. The foundation is a non-profit, 501(c)(3) corporation, which raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.

NIDDK. For more information, please visit

DILIN. Additional details on DILIN are available at the project website,

About AstraZeneca.  For more information, please visit:

SOURCE Foundation for the National Institutes of Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
2. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
3. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
4. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
5. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
6. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
7. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
8. Novexel to be Acquired by AstraZeneca
9. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
10. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... , ... Doctors who missed a case of mesothelioma in a 70-year-old Japanese ... push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma has just ... now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan say the ...
(Date:11/28/2015)... ... November 28, 2015 , ... ... teleradiology services, has added Chris Hafey and Claude Hooton to its board of ... Society of North America (RSNA) 2015 Annual Meeting and continues to strategically transform ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):